because of the rapid development of imipenem resistance despite combination therapy , the high proportion of side effects , and the risk of induction of beta-lactam resistance , imipenem/cilastatin can not be recommended for routine treatment of cf-patients with p. aeruginosa infection .
C0020933
imipenem
C0071972
imipenem/cilastatin